Clinical trials using PD-L1 inhibitors have revealed that Bifidobacterium is capable of facilitating antitumor effectiveness, with oral administration of Bifidobacterium alone improving melanoma tumor control to a similar extent as PD-L1-specific antibody therapy, with combination therapy virtually eliminating tumor growth 64. This evidence concerns the gene CD274 and melanoma.